PT-141

PT-141 (also known as Bremelanotide, Vyleesi) is a prominently researched experimental compound classified strictly within the Melanocortin Agonist framework. Operating primarily through advanced pharmacological pathways, it functions by central melanocortin pathway. Activates MC4R in the CNS to stimulate sexual desire through brain pathways rather than vascular effects. with a documented biological half-life of roughly 2.7 hours, in preclinical investigative trials and independent academic studies, researchers utilizing PT-141 have documented significant, quantifiable biological outcomes, primarily focusing on sexual arousal, libido. Typical research protocols investigate administering 1500 to 1500mcg via subq pathways 2x/wk. However, it is critically important to understand that while PT-141 demonstrates profound physiological potential in highly controlled laboratory settings, it remains classified strictly as a research chemical and has not been approved by the United States Food and Drug Administration (FDA) for human therapeutic, diagnostic, or dietary consumption. Independent chemical analysis via rigorous third-party Certificate of Analysis (COA) testing utilizing High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS) remains the industry gold standard for verifying its base elemental stability when reconstituted appropriately in sterile bacteriostatic water.